Esophageal Squamous Cell Carcinoma, Locally Advanced Carcinoma
Conditions
Keywords
Drug: Tislelizumab, Chemotherapy
Brief summary
This is a single-arm，open-label study to evaluate the efficacy and safety of tislelizumab plus chemotherapy for conversion therapy of patients with locally nonresectable ESCC.
Interventions
DRUGTislelizumab
The 1st to 3rd doses were administered concurrently with FP regimen chemotherapy, 200 mg Tislelizumab each, on D1, D22 and D43 by intravenous infusion. In patients with successful conversion, one dose of 200 mg was administered 21 days after surgery in concurrent with the 4th to 6th cycles of 5-Fu, then 6 cycles of 200 mg Tislelizumab as adjuvant therapy; in patients with failed conversion, chemotherapy combined with tislelizumab were administered, with or without radiation therapy.
DRUG5-FU
A FP regimen with 5-Fu 850mg/m\^2 d1-4 + cis-platinum 850mg/m\^2 d1-4 was used, on D1, D22 and D43 infused intravenously. 3 cycles of 5-Fu 850mg/m\^2 d1-4 adjuvant chemotherapy were started at 21 days after surgery in patients with a successful conversion. In patients with failed conversion, chemotherapy combined with tislelizumab were administered, with or without radiation therapy.
DRUGcis Platinum
A FP regimen with 5-Fu 850mg/m\^2 d1-4 + cis-platinum 850mg/m\^2 d1-4 was used, on D1, D22 and D43 infused intravenously. In patients with failed conversion, chemotherapy combined with tislelizumab were administered, with or without radiation therapy.
Sponsors
The First Affiliated Hospital with Nanjing Medical University
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
Yes
Inclusion criteria
1. Aged between 18 and 75 years; 2. Understand the research procedure and content, and voluntarily sign written informed consent; 3. Patients with clinical stage IIA-IIIB esophageal cancer were assessed by endoscopic ultrasonography, CT/MRI and other imaging. 4. Esophageal surgery experts believe that patients with potentially resectable esophageal cancer 5. No blood transfusion was received 3 months before enrollment; 6. ECOG PS score: 0-1.
Exclusion criteria
* Patients meeting any of the following criteria are not eligible for inclusion: 1. Women who are pregnant or breastfeeding; 2. previous or concurrent malignancy; 3. Participated in clinical trials of other drugs within four weeks; 4. Have a history of immune deficiency, or other acquired or congenital immune deficiency diseases, or have a history of organ transplantation, or have a history of serious chronic autoimmune diseases, such as systemic lupus erythematosus, etc. 5. Patients with hypersensitivity to human or mouse monoclonal antibodies; 6. Those who have a history of psychotropic drug abuse and cannot get rid of it or have mental disorders; 7. According to the judgment of the researcher, there are serious concomitant diseases that endanger the patient's safety or affect the patient's ability to complete the study.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Incidence of translational treatment AE | up to 2 years | Translational treatment-related AEs resulted in rates of surgery that were more than 30 days late or inoperable than originally planned |
| MPR | up to 2 years | The proportion of patients whose primary tumor cell residual was less than 10% in the total number of patients enrolled after transformation therapy |
| pCR | up to 2 years | Pathological complete response refers to that no tumor component or a small amount of carcinoma in situ component can be found on the horizontal line of pathological section after systemic treatment and surgical resection of the lesion. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| R0 resection rate | up to 2 years | The proportion of patients who completed R0 resection through 3 cycles of immunotherapy combined with chemotherapy in the total enrolled population.R0 finger resection margin under microscope was negative. |
| Disease-free Survival，DFS | up to 2 years | The time from randomization to disease recurrence or death due to disease progression |
Countries
China
Contacts
Primary ContactTongpeng Xu, PhD
Outcome results
None listed